{"prompt": "['NOVARTIS', 'Global Clinical Development - General Medicine', 'QVM149B (Indacaterol acetate/Glycopyrronium bromide/Mometasone', 'furoate)', 'Clinical Trial Protocol CQVM149B2306 / NCT03158311', 'A multicenter, partially-blinded, randomized, 24-week,', 'parallel-group, non-inferiority, open-label active controlled', 'study to compare the efficacy and safety of QVM149 with a', 'free triple combination of salmeterol/fluticasone +', 'tiotropium in patients with uncontrolled asthma', 'Document type:', 'Amended Protocol Version', 'EUDRACT number:', '2017-000136-34', 'Version number:', 'v02 Clean', 'Clinical trial phase:', 'IIIb', 'Release date:', '16-Nov-2017', 'Property of Novartis', 'Confidential', 'May not be used, divulged, published, or otherwise disclosed', 'without the consent of Novartis', 'Clinical Trial Protocol Template Version 3.2 (July 2016)']['Novartis', 'Confidential', 'Page 2', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'Table of contents', 'Table of contents', '2', 'List of tables', '5', 'List of figures', '5', 'List of abbreviations', '6', 'Glossary of terms', '8', 'Amendment 2', '9', 'Amendment 1', '10', 'Protocol summary', '12', '1', 'Introduction', '15', '1.1', 'Background', '15', '1.2', 'Purpose', '16', '2', 'Study objectives and endpoints', '16', '2.1', 'Study Objectives and Endpoints', '17', '3', 'Investigational plan', '18', '3.1', 'Study design', '18', '3.2', 'Rationale for study design', '20', '3.3', 'Rationale for dose/regimen, route of administration and duration of treatment', '21', '3.4', 'Rationale for choice of comparator', '23', '3.5', 'Purpose and timing of interim analyses/design adaptations', '23', '3.6', 'Risks and benefits', '23', '4 Population', '25', '4.1', 'Inclusion criteria', '25', '4.2', 'Exclusion criteria', '26', '5 Treatment', '29', '5.1', 'Study treatment', '29', '5.1.1', 'Investigational and control drugs', '29', '5.1.2', 'Additional treatment', '30', '5.2', 'Treatment arms', '30', '5.3', 'Treatment assignment and randomization', '30', '5.4', 'Treatment blinding', '31', '5.5', 'Treating the patient', '31', '5.5.1', 'Patient numbering', '31', '5.5.2', 'Dispensing the study drug', '32', '5.5.3', 'Handling of study and additional treatment', '32']['Novartis', 'Confidential', 'Page 3', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', '5.5.4', 'Instructions for prescribing and taking study treatment', '33', '5.5.5', 'Permitted dose adjustments and interruptions of study treatment', '34', '5.5.6', 'Rescue medication', '35', '5.5.7', 'Concomitant medication', '36', '5.5.8', 'Prohibited medications', '36', '5.5.9', 'Emergency breaking of assigned treatment code', '39', '5.6', 'Study Completion and Discontinuation', '39', '5.6.1', 'Study completion, post-study treatment and end of trial', '39', '5.6.2', 'Discontinuation of Study Treatment', '40', '5.6.3', 'Withdrawal of informed consent', '41', '5.6.4', 'Lost to follow-up', '41', '5.6.5', 'Early study termination by the sponsor', '41', '6', 'Visit schedule and assessments', '41', '6.1', 'Information to be collected on screening failures', '44', '6.2', 'Patient demographics/other baseline characteristics', '45', '6.3', 'Treatment exposure and compliance', '45', '6.4', 'Efficacy', '45', '6.4.1', 'Health Status (Patient Reported Outcomes)', '46', '6.4.2', 'Spirometry', '47', '48', '6.4.4', 'Worsening of asthma', '48', '6.4.5', 'Asthma Exacerbation', '49', '50', '6.4.7', 'Appropriateness of efficacy assessments', '51', '6.5', 'Safety', '51', '6.5.1', 'Physical examination', '51', '6.5.2', 'Vital signs', '52', '6.5.3', 'Height and weight', '52', '6.5.4', 'Laboratory evaluations', '52', '6.5.5', 'Electrocardiogram (ECG)', '52', '6.5.6', 'Pregnancy and assessments of fertility', '53', '6.5.7', 'Appropriateness of safety measurements', '53', '53', '53', '54', '54']\n\n###\n\n", "completion": "END"}